Company intelligence / Profile preview

Mipa

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

MIPA is an emerging biotechnology company focused on the development of next-generation molecular imaging agents and radiopharmaceuticals for personalized medicine. The company leverages a proprietary platform to design high-affinity ligands targeting biomarkers such as PSMA and FAP, aiming to improve the detection and treatment of various cancers. By integrating advanced imaging with targeted therapy, MIPA seeks to provide clinicians with more precise tools for patient stratification and monitoring. Their current pipeline is primarily in the pre-clinical stage, focusing on optimizing lead candidates for clinical entry.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall moleculeDiagnostic imaging agent
Industry: Biotech

Beyond the preview

Go deeper on Mipa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mipa.

Explore the full profile